Navigator Guided e-Psychoeducational Intervention
Navigator Guided e-Psychoeducational Intervention for Prostate Cancer Patients and Their Caregivers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer and Research Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men newly diagnosed (within 6 months) with biopsy confirmed case of prostate cancer
- 40 - 80 years of age
- Able to speak and read English
- Live within 120 miles of a healthcare treatment facility
- Have no documented or observable visual, auditory, psychiatric, or neurological disorders that would interfere with study participation
- Be able to complete telephone interviews
- Have not completed the first course of treatment
- Have a family member/caregiver willing to participate
- Capable of providing written consent for study participation. Men diagnosed with early stage, locally advanced or metastatic disease or men who are on active surveillance will be eligible to participate in this study.
- Caregiver must be aged 18 or older
- Caregiver must be identified by patient as their caregiver (i.e., provider of emotional and/or physical care)
- Caregiver must have not been diagnosed with cancer in the previous year or be receiving cancer treatment
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PHI Navigator
Personalized Health Information Navigator (PHIN).
|
The application (or "app") titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology.
The PHIN provides patient-centered education.
At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad.
The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs.
|
|
NCI Information Booklets (IB)
National Cancer Institute (NCI) Information Booklets (IB).
|
Participants will receive a packet of information booklets ("What You Need to Know About Prostate Cancer"; "Taking Time: Support for People with Cancer"; and "Facing Forward, Life After Cancer Treatment") that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support.
At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider.
The community navigator will leave the print materials with the participant for 6-weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Final Survey Results per Study Arm
Time Frame: 6 months post baseline survey
|
Investigators plan to assess if the psycho-educational intervention, PHIN, delivered by a CN is more efficacious as compared to NCI Information Booklets (IB) delivered by a CN.
Participants will be asked to complete a baseline set of surveys and follow-up surveys at three additional time points: (1) 6 weeks after receiving the educational intervention; (2) after the follow-up decision with their doctor or health care provider; and (3) 6 months after the baseline surveys were done.
|
6 months post baseline survey
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: B. Lee Green, PhD, H. Lee Moffitt Cancer Center and Research Institute
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MCC-17455
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
NCT07156045RecruitingProstate Cancer Castration-resistant Prostate Cancer
-
NCT03880422RecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
-
NCT07650240Not yet recruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Advanced Prostate Cancer | Localized Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Adenocarcinoma of the Prostate | Metastatic Prostate Adenocarcinoma | Advanced Prostate Adenocarcinoma | Recurrent Prostate Adenocarcinoma
-
NCT03477864WithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
NCT01469338TerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
-
NCT07298239RecruitingProstate Cancer Castration-resistant Prostate Cancer
-
NCT02144649CompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
-
NCT01882985CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
-
NCT04457245TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
-
NCT00121238CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
Clinical Trials on Personalized Health Information Navigator (PHIN)
-
NCT03256929Unknown
-
NCT02943876Completed
-
NCT03583203CompletedSmoking Cessation | COPD | Severe Mental Disorder
-
NCT07330323RecruitingSkin Cancer | Management | Low Risk
-
NCT06494319RecruitingPTSD | Trauma and Stressor Related Disorders | Traumatic Brain Injury
-
NCT05406687Completed